Advertisement
Canada markets closed

  • S&P/TSX

    22,059.03
    -184.99 (-0.83%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • DOW

    39,375.87
    +67.87 (+0.17%)
     

  • CAD/USD

    0.7332
    -0.0015 (-0.20%)
     

  • CRUDE OIL

    83.44
    -0.44 (-0.52%)
     

  • Bitcoin CAD

    77,380.04
    +3,025.40 (+4.07%)
     

  • CMC Crypto 200

    1,175.44
    -33.25 (-2.75%)
     

  • GOLD FUTURES

    2,399.80
    +30.40 (+1.28%)
     

  • RUSSELL 2000

    2,026.73
    -9.90 (-0.49%)
     

  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     

  • NASDAQ

    18,352.76
    +164.46 (+0.90%)
     

  • VOLATILITY

    12.48
    +0.22 (+1.79%)
     

  • FTSE

    8,203.93
    -37.33 (-0.45%)
     

  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     

  • CAD/EUR

    0.6762
    -0.0030 (-0.44%)
     

Merck to buy Elanco Animal Health's aqua business for $1.3 bln

Reuters
Updated ·1 min read

Feb 5 (Reuters) — Merck said on Monday it had agreed to buy Elanco Animal Health's aqua business for $1.3 billion in cash, to strengthen its portfolio of aquatic healthcare products.

Shares in Elanco, which makes animal health products, rose almost 8% in premarket trading after the news.

The acquisition will help Merck gain access to the DNA-based vaccine Clynav, which protects atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment.

Merck will also have access to Elanco's manufacturing facilities in Canada and Vietnam, as well as a research facility in Chile.

The acquisition is expected to be completed by mid-year.

(Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru; Editing by Savio D'Souza and Sriraj Kalluvila)